Aimmune Therapeutics (AIMT) Upgraded to “Hold” by BidaskClub

Aimmune Therapeutics (NASDAQ:AIMT) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

AIMT has been the topic of a number of other reports. Piper Jaffray Companies set a $38.00 price target on Aimmune Therapeutics and gave the company a “buy” rating in a research note on Saturday, October 21st. Credit Suisse Group set a $45.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 11th. Zacks Investment Research downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 8th. Wedbush reiterated an “outperform” rating and set a $70.00 target price on shares of Aimmune Therapeutics in a research report on Friday, December 1st. Finally, Roth Capital started coverage on Aimmune Therapeutics in a research report on Monday, November 20th. They set a “buy” rating and a $60.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $57.25.

Aimmune Therapeutics (NASDAQ AIMT) traded up $2.10 during trading on Thursday, hitting $38.68. The company had a trading volume of 570,252 shares, compared to its average volume of 420,109. Aimmune Therapeutics has a 12-month low of $15.97 and a 12-month high of $40.65. The stock has a market capitalization of $1,967.42, a P/E ratio of -16.46 and a beta of -0.82.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.09. research analysts predict that Aimmune Therapeutics will post -2.51 earnings per share for the current fiscal year.

In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 1,648 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $35.87, for a total transaction of $59,113.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Daniel C. Md Adelman sold 3,283 shares of the business’s stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $40.00, for a total value of $131,320.00. Following the sale, the insider now owns 3,283 shares in the company, valued at $131,320. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 134,294 shares of company stock worth $5,097,144. 24.56% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AIMT. Schwab Charles Investment Management Inc. raised its holdings in shares of Aimmune Therapeutics by 21.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 105,689 shares of the biotechnology company’s stock worth $2,173,000 after acquiring an additional 18,632 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Aimmune Therapeutics by 16.9% in the second quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock worth $2,700,000 after acquiring an additional 19,016 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Aimmune Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 1,634 shares during the last quarter. Teachers Advisors LLC raised its holdings in shares of Aimmune Therapeutics by 42.1% in the second quarter. Teachers Advisors LLC now owns 63,037 shares of the biotechnology company’s stock worth $1,296,000 after acquiring an additional 18,688 shares during the last quarter. Finally, TIAA CREF Investment Management LLC raised its holdings in shares of Aimmune Therapeutics by 34.1% in the second quarter. TIAA CREF Investment Management LLC now owns 95,247 shares of the biotechnology company’s stock worth $1,958,000 after acquiring an additional 24,226 shares during the last quarter. 73.54% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/11/aimmune-therapeutics-aimt-upgraded-to-hold-by-bidaskclub.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply